Patents by Inventor William P. Forrest, JR.

William P. Forrest, JR. has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220089738
    Abstract: The invention relates to stable formulations of antibodies against human programmed death receptor PD-1, or antigen binding fragments thereof and a PH20 variant or fragment thereof. The invention further provides methods for treating various cancers with formulations of the invention. In some embodiments of the methods of the invention, the formulations are administered to a subject by subcutaneous administration.
    Type: Application
    Filed: September 23, 2021
    Publication date: March 24, 2022
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Yogita Krishnamachari, Sachin Mittal, Sahil S. Sangani, William P. Forrest, JR., Yongchao Su, Xi Zhao
  • Publication number: 20210380694
    Abstract: The invention relates to stable formulations of antibodies against human programmed death receptor PD-1, or antigen binding fragments thereof. In some embodiments the formulations of the invention comprise between 5-250 mg/mL anti-PD-1 antibody, or antigen binding fragment thereof, a buffer, a stabilizer, a surfactant, and an antioxidant in the amounts specified herein. In particular embodiments, the anti-PD-1 antibody is pembrolizumab. The invention further provides methods for treating various cancers with stable formulations of the invention. In some embodiments of the methods of the invention, the formulations are administered to a subject by intravenous or subcutaneous administration.
    Type: Application
    Filed: November 6, 2019
    Publication date: December 9, 2021
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: William P. Forrest, Jr., Chakravarthy Nachu Narasimhan, Yogita Krishnamachari
  • Publication number: 20200147213
    Abstract: The invention relates to stable formulations of antibodies against human programmed death receptor PD-1, or antigen binding fragments thereof. In some embodiments the formulations of the invention comprise between 5-200 mg/mL anti-PD-1 antibody, or antigen binding fragment thereof. The invention further provides methods for treating various cancers with stable formulations of the invention. In some embodiments of the methods of the invention, the formulations are administered to a subject by intravenous or subcutaneous administration.
    Type: Application
    Filed: May 1, 2018
    Publication date: May 14, 2020
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Manoj K. Sharma, Wendy Benjamin, Sarita Mittal, Ashwin Basarkar, Chakravarthy Nachu Narasimhan, Ramesh S. Kashi, Mohammed Shameem, Soumendu Bhattacharya, William P. Forrest, JR., Yogita Krishnamachari